Article

Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand

Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Siriraj Hospital, Mahidol University, Prannok Road, Bangkok, Thailand.
International Journal of Infectious Diseases (Impact Factor: 2.33). 10/2007; 11(5):402-6. DOI: 10.1016/j.ijid.2006.09.011
Source: PubMed

ABSTRACT To determine the efficacy and safety of colistin (colistimethate sodium) produced by a local pharmaceutical company in Thailand for the treatment of infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa and Acinetobacter baumannii.
Patients hospitalized at Siriraj Hospital between January 2005 and April 2006, who had infections caused by MDR P. aeruginosa or A. baumannii, were enrolled in the study. Colistin (colistimethate sodium) at a dosage of 5 mg/kg/day was given intravenously in two divided doses. Primary outcomes were the clinical response and 30-day mortality; secondary outcomes were microbiological response and adverse events.
Ninety-three patients infected with MDR P. aeruginosa and A. baumannii were enrolled. Seventy-eight patients (71 with A. baumannii and seven with P. aeruginosa) received colistin, whereas 15 patients (12 with A. baumannii and three with P. aeruginosa) received other antibiotics. The mean age, gender, underlying conditions and severity of illness of the patients in both groups were not significantly different. In the colistin group, 63 patients (80.8%) had a favorable clinical response and 94.9% had a microbiological response. The overall mortality of the patients in the colistin group was 46.2% and that in the non-colistin group was 80%. Nephrotoxicity was found in 24 patients (30.8%) in the colistin group and 17 of them had predisposing factors contributing to their renal dysfunction. No neurotoxicity was observed among the 78 patients.
Locally produced colistin appears to be safe and effective for the treatment of infections caused by MDR P. aeruginosa and A. baumannii in Thai adult patients.

Download full-text

Full-text

Available from: Pattarachai Kiratisin, Dec 27, 2014
2 Followers
 · 
143 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper proposes an adaptive channel selection method that reduces signal distortion due to frequency selective fading and thereby improving the performance of mobile communication. In this method a channel is adaptively selected by estimating current channel condition with mean square decision error as a measure. This selected frequency channel corresponds to the channel in which the delayed signals add-up inphase. Hence, BER performance is improved with the proposed scheme. Computer simulation results show the effectiveness of the proposed scheme for a system with multiple terminals and also for a multiple base station (cellular) system
    Communications, 1999. ICC '99. 1999 IEEE International Conference on; 02/1999
  • [Show abstract] [Hide abstract]
    ABSTRACT: Uses genetic algorithms (GA) for planning the stages of the trajectory of a robot arm called Jeca III. First, the GAs are used for planning the trajectory in the cartesian plane with obstacle avoidance, and some new operations, like crossover, are shown. Second, planning in the joint spaces are implemented using the classical GA with some modifications. This stage is divided into two parts: initial positioning and incremental positioning. The initial positioning has the purpose of locating the end effector of the robot arm in the first point of the trajectory, and the incremental positioning of moving the end effector to the next point of the trajectory. The result is a complete trajectory planning with the GAs, demonstrating the flexibility of this technique of artificial intelligence
    Robot Motion and Control, 1999. RoMoCo '99. Proceedings of the First Workshop on; 02/1999
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acinetobacter baumannii is a highly resilient, gram-negative coccobacillus that thrives within the unique and complex ecological setting of an intensive care unit. This evolving pathogen has now surpassed human capacity to create new antimicrobials, and has led physicians into a concerning era for hospital-acquired infections. This review presents the available evidence on the therapeutic strategies for A. baumannii infection, with a particular focus on clinical human data. The utility of existing and older antimicrobials such as sulbactam and the polymyxins are explored, as well as, the potential role of newer agents such as tigecycline. Other important adjunctive strategies such as pharmacodynamic target attainment and infection control implementation are briefly discussed. It is now clear that new antimicrobials with unique mechanisms of action are urgently required to combat the rising trends seen globally with drug-resistant A. baumannii.
    Seminars in Respiratory and Critical Care Medicine 01/2008; 28(6):662-71. DOI:10.1055/s-2007-996413